Injectable solution of plerixafor for subcutaneous administration to mobilize hematopoietic stem cells. Employed in transplant centers and oncology units for multiple myeloma and lymphoma patients. Manufactured by biotech firms and distributed to hospitals via specialized pharmaceutical supply chains for procurement